Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves’ Disease - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

July 18, 2007

Last Updated Date

July 19, 2007

Start Date ^†

February 1998

Current Primary Outcome Measures ^†

Original Primary Outcome Measures ^†

Change History

Complete list of historical versions of study NCT00505011 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Original Secondary Outcome Measures ^†

Descriptive Information

Brief Title ^†

Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves’ Disease

Official Title ^†

Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome.

Brief Summary

Cigarette smoking is a well-recognized risk factor of Graves’ disease and, particularly, Graves’ ophthalmopathy. Hence, germline polymorphisms of detoxification genes and genes belonging to the major DNA repair/apoptosis pathways might have an important role in disease susceptibility. In addition, as some of these genes are regulated by thyroid hormones, they could affect the outcome of these patients. Our objective was to assess the influence of the GST, CYP and TP53 gene polymorphisms in the risk of Graves' disease and its outcome.

Detailed Description

Although the role of many polymorphisms of genes related to toxins’ metabolism has been extensively investigated regarding the susceptibility to thyroid cancer, their influence in thyroid autoimmune diseases risk is still largely unknown. Hence, this study was designed to assess the influence of GSTT1, GSTM1, GSTP1, CYP1A1 and 72TP53 polymorphic inheritance on the susceptibility to Graves' disease and to its response to the treatment.

Study Phase

Study Type ^†

Observational

Study Design ^†

Natural History, Cross-Sectional, Case Control, Retrospective/Prospective Study

Condition ^†

Graves' Disease

Intervention ^†

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Completed

Enrollment ^†

1998

Completion Date

February 2007

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria: - Graves' disease patients

Gender

Both

Ages

2 Years and older

Accepts Healthy Volunteers

Yes

Contacts ^††

Location Countries ^†

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00505011

Responsible Party

Secondary IDs ^††

Study Sponsor ^†

University of Campinas, Brazil

Collaborators ^††

Fundação de Amparo à Pesquisa do Estado de São Paulo

Investigators ^†

Principal Investigator:

Laura S Ward, MD, PhD

State University of Campinas- UNICAMP

Information Provided By

University of Campinas, Brazil

Verification Date

July 2007

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.